Implantable cardioverter-defibrillators may benefit certain younger patients with mild–moderate heart dysfunction
· Medical Xpressedited by Swati Mestri, reviewed by Andrew Zinin
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A more than a decade-long medical trial has opened the way for potentially life-saving treatment options for patients with mild-to-moderate heart conditions. Internationally recognized cardiac expert Flinders University Professor Joseph Selvanayagam, from Adelaide's Heart & Vascular, presented his findings at the European Society of Cardiology Congress (ESC 2026) in Munich on Friday. The breakthrough has also been published in JAMA.
The trial, involving 18 sites across Australia, Germany and the United Kingdom, examined whether a medical device currently used for patients with severe heart conditions could treat a wider range of patients.
An implantable cardioverter-defibrillator (ICD) is a small device placed in the body that can detect and correct dangerous heart rhythms that may otherwise cause sudden cardiac death. ICDs are currently offered only to patients with severely reduced heart function.
Selvanayagam's research investigated another group of patients with mild-to-moderate heart dysfunction; a left ventricular ejection fraction (LVEF of 36%–50%); and scarring in the heart muscle identified by cardiac MRI. The trial examined whether ICD implantation could reduce sudden cardiac death or serious ventricular arrhythmia in this group of patients.
While the trial did not identify a statistically significant reduction with ICD use in the primary endpoint of sudden cardiac death or serious ventricular arrhythmia across all age groups, it did so in a prespecified analysis of patients younger than 70 years. Further, ICD implantation was associated with a reduction in the secondary endpoint of sudden cardiac death in the total cohort. This is the first randomized trial designed to help inform clinicians deciding about ICD implantation in patients with heart scarring and an LVEF of 36%–50%.
"An ICD is like having a personal paramedic for your heart, 24/7," Selvanayagam said. "But the treatment gap right now is that most patients who die suddenly from a heart event don't have underlying severe heart dysfunction, so currently don't get offered an ICD because it is outside accepted treatment guidelines.
"This research has made a new finding that could potentially save lives. The reduction in sudden cardiac death and the benefit observed in younger patients provide important insights for individual treatment decisions.
"If you have mild to moderately reduced heart function due to a cardiomyopathy or previous heart attack, then you should have a cardiac MRI. If you then have significant scarring in your cardiac MRI, you should probably have a discussion with your cardiologist about whether an ICD should be implanted, particularly if you are younger than 70 years."
Publication details
Joseph B. Selvanayagam et al, Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%, JAMA (2026). DOI: 10.1001/jama.2026.17078
Journal information: Journal of the American Medical Association
Key medical concepts
Defibrillators, ImplantableDeath, Sudden, Cardiac
Clinical categories
Cardiology Provided by Flinders University Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Implantable cardioverter-defibrillators may benefit certain younger patients with mild–moderate heart dysfunction (2026, August 29) retrieved 29 August 2026 from https://medicalxpress.com/news/2026-08-implantable-cardioverter-defibrillators-benefit-younger.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.